World's Best Scientists 2026 revealed!
Tim H. Brümmendorf

Tim H. Brümmendorf

D-Index & Metrics

Biology and Biochemistry

D-Index
68
Citations
17462
World Ranking
7751
National Ranking
567

Tim H. Brümmendorf publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Tim H. Brümmendorf sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 413 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 848 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 949 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 840 scientists 207–216 publications: 733 scientists 217–226 publications: 708 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 417 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 196 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 59 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 524 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Tim H. Brümmendorf D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Tim H. Brümmendorf sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 316 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 899 scientists 52–53 D-Index: 1,025 scientists 54–55 D-Index: 1,149 scientists 56–57 D-Index: 1,235 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,162 scientists 62–63 D-Index: 1,130 scientists 64–65 D-Index: 1,031 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 714 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 71 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 68 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Tim H. Brümmendorf is affiliated with RWTH Aachen University in Germany. Their research primarily focuses on the field of medicine, with a particular concentration in hematology, genetics, and molecular biology. Their scholarly work covers various topics in oncology and physiology as well.

The subfields deeply explored in their research include:

  • Hematology
  • Genetics
  • Molecular Biology
  • Oncology
  • Physiology

The principal research topics addressed by Brümmendorf encompass:

  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Acute Myeloid Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Telomeres, Telomerase, and Senescence
  • Acute Lymphoblastic Leukemia Research

Their publication record includes contributions to several well-known journals, notably:

  • Blood
  • Leukemia
  • HemaSphere
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances

Recent papers that exemplify Brümmendorf's research focus include:

  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial, 2022, Leukemia
  • Dexamethasone nanomedicines for COVID-19, 2020, Nature Nanotechnology
  • CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome, 2021, Blood
  • Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis, 2020, Cell stem cell
  • Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?, 2020, Blood

Their frequent co-authors, with whom they have collaborated extensively, include:

  • Steffen Koschmieder
  • Andreas Hochhaus
  • Fabian Beier
  • Susanne Isfort
  • Andreas Burchert

Best Publications

  • Aging of blood can be tracked by DNA methylation changes at just three CpG sites.

    Carola Ingrid Weidner;Qiong Lin;Carmen Maike Koch;Lewin Eisele

  • Telomere Fluorescence Measurements in Granulocytes and T Lymphocyte Subsets Point to a High Turnover of Hematopoietic Stem Cells and Memory T Cells in Early Childhood

    Nathalie Rufer;Tim H. Brümmendorf;Steen Kolvraa;Claus Bischoff

  • Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

    Jorge E. Cortes;Dong Wook Kim;Hagop M. Kantarjian;Tim H. Brümmendorf;Tim H. Brümmendorf

  • Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    Susanne Saussele;Johan Richter;Joelle Guilhot;Franz X Gruber

  • Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    Jorge E. Cortes;Hagop M. Kantarjian;Tim H. Brümmendorf;Dong Wook Kim

  • Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Jorge E. Cortes;Carlo Gambacorti-Passerini;M. W. Deininger;Michael J. Mauro

  • Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

    H. Jean Khoury;Jorge E. Cortes;Hagop M. Kantarjian;Carlo B. Gambacorti-Passerini

  • Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Rüdiger Hehlmann;Michael Lauseker;Susanne Saußele;Markus Pfirrmann

  • HER-2 amplification is highly homogenous in gastric cancer

    Andreas H. Marx;Lars Tharun;Johanna Muth;Ana-Maria Dancau

  • Telomere length in leukocyte subpopulations of patients with aplastic anemia

    Tim H. Brümmendorf;Jaroslaw P. Maciejewski;Jaroslaw P. Maciejewski;Jennifer Mak;Jennifer Mak;Neal S. Young;Neal S. Young

  • Statins Enhance Migratory Capacity by Upregulation of the Telomere Repeat-Binding Factor TRF2 in Endothelial Progenitor Cells

    Ioakim Spyridopoulos;Judith Haendeler;Carmen Urbich;Tim H. Brummendorf

  • Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry

    Tim H. Brümmendorf;Tessa L. Holyoake;Nathalie Rufer;Michael J. Barnett

  • Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9

    Rebekka K Schneider;Rebekka K Schneider;Monica Schenone;Monica Ventura Ferreira;Rafael Kramann

  • Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.

    Judith C. Marsh;Andrea Bacigalupo;Hubert Schrezenmeier;Andre Tichelli

  • Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

    Artur Gontarewicz;Stefan Balabanov;Gunhild Keller;Riccardo Colombo

  • Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial

    Tim H. Brümmendorf;Tim H. Brümmendorf;Jorge E. Cortes;Cármino Antonio de Souza;Francois Guilhot

  • Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

    Silke Appel;Andreas M. Boehmler;Frank Grünebach;Martin R. Müller

  • Asymmetric Cell Divisions Sustain Long-Term Hematopoiesis from Single-sorted Human Fetal Liver Cells

    Tim H. Brummendorf;Wieslawa Dragowska;J.Mark J.M. Zijlmans;Gayle Thornbury

  • Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

    Sarah Minner;Birte Jessen;Lars Stiedenroth;Eike Burandt

  • Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.

    Hagop M. Kantarjian;Jorge E. Cortes;Dong Wook Kim;H. Jean Khoury

Frequent Co-Authors

Carlo Gambacorti-Passerini
Carlo Gambacorti-Passerini University of Milano-Bicocca
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Lothar Kanz
Lothar Kanz University of Tübingen
Stefan W. Krause
Stefan W. Krause University of Erlangen-Nuremberg
Wolfgang E. Berdel
Wolfgang E. Berdel University of Münster
Hermann Einsele
Hermann Einsele University of Würzburg
Satu Mustjoki
Satu Mustjoki University of Helsinki

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding your studies in Biology and Biochemistry opens doors to a variety of online degree programs and career options in the health and life sciences. Students with a foundation in these areas may progress to advanced roles by pursuing specialized education online.

For example, many professionals interested in leadership or policy can explore doctoral programs for healthcare administration, which focus on advanced management skills within healthcare systems. Those aiming for pharmaceutical careers can consider enrolling in a best online pharmacy school to gain high-level expertise in drug development, clinical practice, and research.

For students passionate about physical health and sports, earning a sports science degree online provides a path to careers in fitness, athletic coaching, or rehabilitation. Similarly, those seeking to accelerate their entry into the field may benefit from an accelerated kinesiology degree online to quickly qualify for work in exercise therapy, sports medicine, or wellness.

With these flexible online pathways, students can tailor their further education to their interests and career goals—all while benefiting from the convenience and accessibility of remote learning.

Best Scientists Citing Tim H. Brümmendorf

Trending Scientists

Recently Published Articles